LCM
GALT icon

Laurion Capital Management’s Galectin Therapeutics GALT Stock Holding History

Laurion Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-171,543
Closed -$877K – 983
2019
Q1 		$877K Buy
171,543
+77,145
+82% +$370K 0.01% 528
2018
Q4 		$324K Buy
+94,398
New +$451K 0.01% 796

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Laurion Capital Management's GALT Position: Q2 2019 in Review

Laurion Capital Management sold out of Galectin Therapeutics (GALT) in Q2 2019, closing a stake of 171,543 shares — an estimated $877K sold.

Laurion Capital Management first reported a position in GALT in Q4 2018 and held it in 2 quarters. The position peaked at $877K in Q1 2019. 76 funds tracked by Wall St. Rank hold GALT as of Q2 2019.

  • Laurion Capital Management reported no remaining Galectin Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Laurion Capital Management sold 171,543 Galectin Therapeutics shares in Q2 2019, an estimated $877K.
  • Laurion Capital Management first reported a position in Galectin Therapeutics in Q4 2018 and held it in 2 quarters.
  • Laurion Capital Management's Galectin Therapeutics position peaked at $877K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.